No connection

Search Results

MDGL vs RDY

MDGL
Madrigal Pharmaceuticals, Inc.
NEUTRAL
Price
$518.58
Market Cap
$11.9B
Sector
Healthcare
AI Confidence
85%
RDY
Dr. Reddy's Laboratories Limited
BEARISH
Price
$13.72
Market Cap
$11.45B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
MDGL
--
RDY
19.06
Forward P/E
MDGL
40.53
RDY
25.09
P/B Ratio
MDGL
19.65
RDY
17.01
P/S Ratio
MDGL
12.41
RDY
0.03
EV/EBITDA
MDGL
-37.71
RDY
-0.0

Profitability

Gross Margin
MDGL
94.14%
RDY
55.18%
Operating Margin
MDGL
-18.57%
RDY
16.42%
Profit Margin
MDGL
-30.08%
RDY
16.36%
ROE
MDGL
-42.49%
RDY
16.1%
ROA
MDGL
-16.3%
RDY
7.96%

Growth

Revenue Growth
MDGL
210.8%
RDY
4.4%
Earnings Growth
MDGL
--
RDY
-14.3%

Financial Health

Debt/Equity
MDGL
0.58
RDY
0.18
Current Ratio
MDGL
4.01
RDY
1.88
Quick Ratio
MDGL
3.6
RDY
1.18

Dividends

Dividend Yield
MDGL
--
RDY
0.67%
Payout Ratio
MDGL
0.0%
RDY
11.82%

AI Verdict

MDGL NEUTRAL

MDGL presents a stark contrast between fundamental financial health and explosive growth potential. The Piotroski F-Score of 1/9 indicates severe underlying financial weakness and a lack of operational efficiency, while the absence of an Altman Z-Score prevents a definitive bankruptcy risk assessment. However, this is offset by massive YoY revenue growth of 210.80% and a strong liquidity position (Current Ratio 4.01). The stock trades at a significant premium with a Price/Book of 19.65, and bearish insider activity from the CEO and CFO suggests a disconnect between analyst optimism and internal sentiment.

Strengths
Explosive revenue growth (210.80% YoY)
Strong short-term liquidity with a Current Ratio of 4.01
High Gross Margin (94.14%) indicating strong pricing power for its product
Risks
Severe fundamental weakness as indicated by a Piotroski F-Score of 1/9
Consistent lack of profitability with a -30.08% profit margin
Extreme valuation premiums (P/B of 19.65 and P/S of 12.41)
RDY BEARISH

RDY exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and very low leverage, but it is severely overvalued based on deterministic models. The current price of $13.72 trades at a massive premium to both the Graham Number ($3.61) and the Intrinsic Value ($5.04). This valuation gap is exacerbated by negative earnings growth (-14.30%) and a high PEG ratio of 3.77, suggesting the market is pricing in growth that is not currently manifesting in the data. While the balance sheet is healthy, the combination of bearish technicals and fundamental overvaluation makes the risk-reward profile unattractive.

Strengths
Very low Debt/Equity ratio (0.18) indicating minimal insolvency risk
Strong liquidity with a Current Ratio of 1.88
Healthy Return on Equity (ROE) of 16.10%
Risks
Extreme overvaluation relative to Graham Number and Intrinsic Value
Negative year-over-year earnings growth (-14.30%)
High PEG ratio (3.77) indicating price is disconnected from growth

Compare Another Pair

MDGL vs RDY: Head-to-Head Comparison

This page compares Madrigal Pharmaceuticals, Inc. (MDGL) and Dr. Reddy's Laboratories Limited (RDY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile